23/10/2026 - Campus Can Ruti, Research
HIPRA's COVID-19 vaccine generates a broad and long-lasting immune response to SARS-CoV-2 in adolescents, as demonstrated in adults
A clinical trial involving 240 adolescents aged 12 to 17 has shown that HIPRA's COVID-19 vaccine, BIMERVAX®, administered as a booster dose, induces a broad immune response against different SARS-CoV-2 variants, comparable to that observed in adults and sustained for at least one year. The study, published in Pediatrics, was led by IrsiCaixa, IGTP, VHIR and HIPRA as part of the European RBDCOV project.
